Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Cancer Care and the Power of Patient Voices

What trends today will kick off a new age for oncology practices? Madelyn Trupkin Herzfeld, CEO for Carevive, which is building technologies that improve the cancer patient treatment experience and survival outcomes while lowering costs, shared her thoughts and insights. With the pandemic adding layers of complexity to the already challenging world of cancer…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

What trends today will kick off a new age for oncology practices? Madelyn Trupkin Herzfeld, CEO for Carevive, which is building technologies that improve the cancer patient treatment experience and survival outcomes while lowering costs, shared her thoughts and insights.

With the pandemic adding layers of complexity to the already challenging world of cancer care, Herzfeld said it wasn’t easy for healthcare providers to add new technology solutions during this time.

“What you’ve heard most about is patients fearing coming in for screenings,” Herzfeld said. “So diagnostic testing and new cancer cases certainly haven’t been identified, because patients have said they are going to put the screening off until after the pandemic.”

One trend coming out of the pandemic is virtual consultations, which Herzfeld believes will continue long after COVID-19.

“Virtual care is finding the right use cases in all areas of healthcare, but particularly in cancer care, where it’s possible to do follow up consults virtually,” Herzfeld said. “You won’t see that go away when the pandemic ends.”

Carevive’s solutions focus on patient-reported outcomes, and Herzfeld shared her excitement on the evolution of cancer care in this area and the many improvements to come.

“Making sure that we understand what the patient is experiencing, what their symptoms are and how can we get in front of them to make the best quality of life when patients have advanced cancer,” Herzfeld said. “So that is taking front and center stage with all stakeholders in the cancer care industry.”

One of the things Carevive is doing to help make cancer treatment better is remote patient monitoring.

“Providers need a scalable technology to do remote patient monitoring, which is a positive thing we’re able to provide them,” Herzfeld said. “We’re also able to provide them with the insights from their data that can really help them improve their practice, improve the treatments they select for patients and improve their symptom management practices.”

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512